Literature DB >> 34792834

Metacognitive training modified for negative symptoms: A feasibility study.

Linda Swanson1,2,3, Matthias Schwannauer1, Tim Bird1, Emma Eliasson1, Audrey Millar2, Steffen Moritz4, Helen Griffiths1.   

Abstract

OBJECTIVE: Although patients often prioritize the treatment of negative symptoms, few psychological interventions targeting negative symptoms exist. This study attempts to fill this gap by piloting a modified metacognitive training programme, specifically targeted at negative symptoms (MCT-N), with a group of patients with prominent negative symptoms.
METHOD: We adopted a mixed methods case series design, providing detailed quantitative data on changes over time, to focus on potential mechanisms underlying the intervention, in combination with qualitative interviews.
RESULTS: The intervention showed good feasibility as demonstrated by the attendance rate, the positive feedback from participants and the multidisciplinary team, and the improvements on negative symptoms observed following the intervention. Multilevel modelling showed that depression, internalized stigma and reflective functioning explained the variance in negative symptoms. DISCUSSION: The pilot study indicated that the intervention has high feasibility and that improvements in negative symptoms can be partially explained by improvements on depression, stigma and reflective functioning.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  depression; mentalization; metacognitive training; negative symptoms; stigma

Mesh:

Year:  2021        PMID: 34792834     DOI: 10.1002/cpp.2692

Source DB:  PubMed          Journal:  Clin Psychol Psychother        ISSN: 1063-3995


  1 in total

1.  Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study.

Authors:  Ellaheh Gohari; Raeanne C Moore; Colin A Depp; Robert A Ackerman; Amy E Pinkham; Philip D Harvey
Journal:  Psychiatry Res       Date:  2022-02-25       Impact factor: 11.225

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.